share_log

8-K: Cassava Sciences' Update on the Investigation of Dr Huaren Wang

8-K: Cassava Sciences' Update on the Investigation of Dr Huaren Wang

8-K:Cassava Sciences对于王华仁博士调查的最新情况
美股SEC公告 ·  07/01 08:03
Moomoo AI 已提取核心信息
Cassava Sciences, Inc., a biopharmaceutical company, has reported its ongoing cooperation with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) regarding investigations into the company and two senior employees. The investigations relate to the company's Phase 2b study of simufilam, a drug candidate for Alzheimer's disease. The SEC has provided new information to Cassava, prompting the Board to empower an Ad Hoc Investigation Committee to conduct an internal investigation. This committee is overseeing the investigation and the company's SEC disclosures related to the matter. Dr. Hoau-Yan Wang, a former scientific collaborator and advisor to Cassava, has been indicted by a federal grand jury for allegedly making false statements in NIH grant...Show More
Cassava Sciences, Inc., a biopharmaceutical company, has reported its ongoing cooperation with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) regarding investigations into the company and two senior employees. The investigations relate to the company's Phase 2b study of simufilam, a drug candidate for Alzheimer's disease. The SEC has provided new information to Cassava, prompting the Board to empower an Ad Hoc Investigation Committee to conduct an internal investigation. This committee is overseeing the investigation and the company's SEC disclosures related to the matter. Dr. Hoau-Yan Wang, a former scientific collaborator and advisor to Cassava, has been indicted by a federal grand jury for allegedly making false statements in NIH grant applications and manipulating research results related to simufilam. Cassava has terminated its consulting relationship with Dr. Wang and removed him from the Cash Incentive Plan. The company is also supplementing its prior disclosures regarding the Phase 2b study, revealing that certain statistical information could have unblinded Dr. Wang to study participants. Cassava is currently conducting two Phase 3 clinical trials of simufilam, with all efficacy data remaining blinded and independent third-party firms handling bioanalysis. The company cautions that forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ materially.
生物制药公司Cassava Sciences正在与美国司法部(DOJ)和证券交易委员会(SEC)合作,调查该公司和两位高级员工。调查涉及该公司治疗阿尔茨海默病的候选药simufilam的2b阶段研究。SEC向Cassava提供了新信息,促使董事会授权成立特别调查委员会进行内部调查。该委员会正在监督调查和公司与此事相关的SEC披露。Cassava的前科学合作者和顾问王浩言博士被联邦大陪审团起诉,涉嫌在NIH批准申请中提供虚假陈述和操纵与simufilam相关的研究结果。Cassava已终止与王博士的咨询关系并将其从现金激励计划中除名。该公司还补充了其关于2b阶段研究的先前披露,揭示了某些统计信息可能使王博士取消对研究参与者的盲化。Cassava目前正在进行两项simufilam的3期临床试验,所有疗效数据仍然保持盲态,并由独立第三方公司进行生物分析。该公司警告称,该报告中的前瞻性陈述受到风险和不确定性的影响,实际结果可能存在重大差异。
生物制药公司Cassava Sciences正在与美国司法部(DOJ)和证券交易委员会(SEC)合作,调查该公司和两位高级员工。调查涉及该公司治疗阿尔茨海默病的候选药simufilam的2b阶段研究。SEC向Cassava提供了新信息,促使董事会授权成立特别调查委员会进行内部调查。该委员会正在监督调查和公司与此事相关的SEC披露。Cassava的前科学合作者和顾问王浩言博士被联邦大陪审团起诉,涉嫌在NIH批准申请中提供虚假陈述和操纵与simufilam相关的研究结果。Cassava已终止与王博士的咨询关系并将其从现金激励计划中除名。该公司还补充了其关于2b阶段研究的先前披露,揭示了某些统计信息可能使王博士取消对研究参与者的盲化。Cassava目前正在进行两项simufilam的3期临床试验,所有疗效数据仍然保持盲态,并由独立第三方公司进行生物分析。该公司警告称,该报告中的前瞻性陈述受到风险和不确定性的影响,实际结果可能存在重大差异。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息